| Symbol | INKT |
|---|---|
| Name | MINK THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 149 FIFTH AVENUE,SUITE 500, NEW YORK, New York, 10010, United States |
| Telephone | +1 212 994-8250 |
| Fax | — |
| — | |
| Website | https://www.minktherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001840229 |
| Description | MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses. Additional info from NASDAQ: |
(80% Positive) MINK THERAPEUTICS, INC. (INKT) Announces Enrollment Update for authorization Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreMiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
Read moreMiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
Read moreMiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
Read moreRyan Barbara 🔴 sold 1.5K shares of MiNK Therapeutics, Inc. (INKT) at $12.80 Transaction Date: Jun 04, 2026 | Filing ID: 260084
Read moreHolcomb John Bradley 🟢 acquired 2.3K shares of MiNK Therapeutics, Inc. (INKT) at $12.38 Transaction Date: Mar 02, 2026 | Filing ID: 253474
Read moreRyan Barbara 🟢 acquired 3.1K shares of MiNK Therapeutics, Inc. (INKT) at $12.38 Transaction Date: Mar 02, 2026 | Filing ID: 253470
Read moreCorvese Brian 🟢 acquired 3.1K shares of MiNK Therapeutics, Inc. (INKT) at $12.38 Transaction Date: Mar 02, 2026 | Filing ID: 253468
Read more